Citigroup Inc. (NYSE:C) Employee Obliged as Alleged Middleman in Insider-Trading
A former Citigroup Inc. (NYSE:C) employee was the alleged middleman in what authorities believe may be an insider trading scheme, according to people familiar with the matter and disclosures in a U.K. court case that wrapped up Thursday. The U.K.’s Financial Conduct Authority is investigating whether David Johnson, who left Citi in 2013, collected details about impending deals from a former colleague and passed them to traders, the people say. The Securities and Exchange Commission is investigating the allegations, the people say. Federal prosecutors in New York also are looking into the alleged insider trading, a person familiar with the matter said.
Citigroup Inc. (NYSE:C), a Financial sector firm, traded 11.77 Million shares in last trading session with closing price of $68.15 per share. Company return on investment (ROI) is 8.50%. Stock value has moved between $48.33 – 74.89 in last one year. Analyst’s mean target price for Citigroup Inc. (NYSE:C) is $80.13 while analysts mean recommendation is 1.90. C EPS growth this year is 22.40%.
On last trading day, salesforce.com, inc. (NYSE:CRM) shares closed at $150.69 per share. CRM market capitalization is 117203.67 with beta of 1.31. Analyst’s mean target price for salesforce.com, inc.(NYSE:CRM) is $182.77 whereas analysts mean recommendation is 1.70. Its weekly performance is -4.14% while year to date (YTD) performance is 10.02%.
In last session CBAK Energy Technology, Inc. (NASDAQ:CBAT) traded 104216 shares and was closed at $0.98. Analyst’s mean target price for CBAT is $2.00. Company is -20.43% away from its 52 week high and is moving 321.85% ahead of its 52 week low. CBAT Gross Margin is -12.10% and its return on assets is -1.70%. CBAK Energy Technology, Inc. (NASDAQ:CBAT) quarterly performance is -4.98% while its price to sale ratio is 1.21.
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a Healthcare sector firm, traded 116615 shares on last trading day with closing price of $3.39 per share. Stock value has moved between $3.23 – 12.56 in last one year. Analyst’s mean target price for Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) is $11.50 while analysts mean recommendation is 1.50. CRVS EPS growth this year is 37.20%.